Payment overview · 2025
General Payments
$311.62
16 reported records · 4 companies
Healthcare provider profile · identity verified
David S Blumenthal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NEW YORK, NY · NPI 1427109826
Verified facts
What the public records show
CMS Open Payments records show David S Blumenthal, M.D. received $311.62 in general payments during 2025 across 16 reported records.
Novartis Pharmaceuticals Corporation accounted for 68.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $212.13 | 68.1% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.40 | 19.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.37 | 7.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.72 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.62 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $212.13 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $15.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
134 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1240 | 349 |
| Ezetimibe | Ezetimibe | 922 | 281 |
| Amlodipine Besylate | Amlodipine Besylate | 726 | 194 |
| Eliquis | Apixaban | 616 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 532 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 488 | 131 |
| Repatha Sureclick | Evolocumab | 457 | 68 |
| Eplerenone | Eplerenone | 361 | 94 |
| Praluent Pen | Alirocumab | 312 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 297 | 88 |
| Irbesartan | Irbesartan | 292 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 83 |
| Valsartan | Valsartan | 251 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 239 | 45 |
| Carvedilol | Carvedilol | 190 | 43 |
| Montelukast Sodium | Montelukast Sodium | 190 | 52 |
| Colchicine | Colchicine | 182 | 56 |
| Potassium Chloride | Potassium Chloride | 181 | 59 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 179 | 54 |
| Atenolol | Atenolol | 150 | 43 |
| Metformin Hcl Er | Metformin Hcl | 143 | 47 |
| Spironolactone | Spironolactone | 143 | 52 |
| Entresto | Sacubitril/Valsartan | 134 | 28 |
| Synthroid | Levothyroxine Sodium | 107 | 26 |
| Furosemide | Furosemide | 100 | 34 |
| Metformin Hcl | Metformin Hcl | 98 | 27 |
| Allopurinol | Allopurinol | 96 | 23 |
| Losartan Potassium | Losartan Potassium | 96 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 21 |
| Farxiga | Dapagliflozin Propanediol | 92 | 20 |
| Jardiance | Empagliflozin | 87 | 21 |
| Vyndamax | Tafamidis | 81 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Azithromycin | Azithromycin | 70 | 52 |
| Lisinopril | Lisinopril | 69 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 20 |
| Alprazolam | Alprazolam | 59 | 18 |
| Digoxin | Digoxin | 56 | 18 |
| Eszopiclone | Eszopiclone | 54 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 50 | 15 |
| Ramipril | Ramipril | 49 | 14 |
| Finasteride | Finasteride | 40 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 13 |
| Omeprazole | Omeprazole | 37 | 12 |
| Xarelto | Rivaroxaban | 37 | 11 |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 12 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Nexletol | Bempedoic Acid | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Multaq | Dronedarone Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Crestor | Rosuvastatin Calcium | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Prednisone | Prednisone | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Mitigare | Colchicine | 17 | suppressed |
| Corlanor | Ivabradine Hcl | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Vyndaqel | Tafamidis Meglumine | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.62 · 16 records | Novartis Pharmaceuticals Corporation | LEQVIO, MOUNJARO, REPATHA, WAINUA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error